Asthma that is unresponsive to usual care

CMAJ. Canadian Medical Association Journal

Volumn 182, Issue 1, 2010, Pages 45-52

  Chapman, Kenneth R ^a   McIvor, Andrew ^b,c  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIHISTAMINIC AGENT; ASCORBIC ACID; AURANOFIN; AYURVEDIC DRUG; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; CYCLOSPORIN A; DAPSONE; ETANERCEPT; FISH OIL; FLUTICASONE; GOLD SALT; HERBACEOUS AGENT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; MAGNESIUM; MEPOLIZUMAB; METHOTREXATE; MONTELUKAST; OMALIZUMAB; PREDNISONE; PROTON PUMP INHIBITOR; SALMETEROL; STEROID; THEOPHYLLINE; TROLEANDOMYCIN; UNINDEXED DRUG; ANTIALLERGIC AGENT; MONOCLONAL ANTIBODY;

ACUPUNCTURE; ADD ON THERAPY; ADJUVANT THERAPY; ADULT; AGRANULOCYTOSIS; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANAPHYLAXIS; ANEMIA; ARM PAIN; ARTHRALGIA; ASEPTIC MENINGITIS; ASPERGILLOMA; ASTHMA; AYURVEDA; BIRTH; BLOOD DYSCRASIA; BREATHING EXERCISE; BRONCHIAL THERMOPLASTY; BRONCHOPLASTY; BRUISING; BURNING SENSATION; CASE REPORT; CHILDHOOD DISEASE; CHIROPRACTIC; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DERMATITIS; DIARRHEA; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSAGE FORM; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; EMERGENCY WARD; EMPHYSEMA; FEMALE; FEVER; FITNESS; FRACTURE; GASTROESOPHAGEAL REFLUX; GENERAL PRACTITIONER; HEMOLYTIC ANEMIA; HERBAL MEDICINE; HOMEOPATHY; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; HYPERTRICHOSIS; HYPNOSIS; INFANCY; INFLAMMATION; INJECTION SITE REACTION; INSECT STING; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEG PAIN; LEUKOPENIA; LIVER FIBROSIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG EDEMA; LUNG FUNCTION TEST; LUNG TOXICITY; METHEMOGLOBINEMIA; NAUSEA; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PAIN; PALLOR; PARESTHESIA; PERIPHERAL NEURITIS; PHARYNGITIS; PHYSICAL EXAMINATION; PROTEINURIA; PRURITUS; PSYCHOSIS; RELAXATION TRAINING; REVIEW; SCREENING TEST; SINGLE DRUG DOSE; SINUSITIS; SKIN INDURATION; SKIN REDNESS; SKIN TEST; SPIROMETRY; STOMATITIS; SYMPTOM; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT REFUSAL; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VITAMIN SUPPLEMENTATION; VOMITING; WHEEZING; HOSPITALIZATION; PATIENT EDUCATION; PATIENT REFERRAL; TREATMENT FAILURE;

ADULT; ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; BRONCHODILATOR AGENTS; FEMALE; HUMANS; PATIENT EDUCATION AS TOPIC; REFERRAL AND CONSULTATION; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; STEROIDS; TREATMENT FAILURE;

EID: 77949411322     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.090089     Document Type: Review

References (92)

1. Krahn MD, Berka C, Langlois P, et al. Direct and indirect costs of asthma in Canada. CMAJ 1996;154:821-31.
2. Ungar WJ, Coyte PC, Chapman KR, et al.; Pharmacy Medication Monitoring Program Advisory Board. The patient level cost of asthma in adults in south central Ontario. Can Respir J 1998;5:463-71.
3. Smith DH, Malone DC, Lawson KA, et al. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 1997;156:787-93.
4. Chapman KR, Ernst P, Grenville A, et al. Control of asthma in Canada: failure to achieve guideline targets. Can Respir J 2001;8(Suppl A):35A-40A.
5. Seung SJ, Mittmann N. Urgent care costs of uncontrolled asthma in Canada, 2004. Can Respir J 2005;12:435-6.
6. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention. GINA executive summary. Eur Respir J 2008;31:143-78.
7. Balter MS, Bell AD, Kaplan AG, et al. Management of asthma in adults. CMAJ 2009. DOI:10.1503/cmaj.080007.
8. Canadian Task Force on Preventive Health Care. New grades for recommendations from the Canadian Task Force on Preventive Health Care. CMAJ 2003;169:207-8.
9. Kaplan AG, Balter MS, Bell AD, et al. Diagnosis of asthma in adults. CMAJ 2009. DOI: 10.1503/cmaj.080006.
10. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836-44.
11. Boulet LP, Becker A, Bérubé D, et al.; Canadian Asthma Consensus Group. Canadian asthma consensus report, 1999. CMAJ 1999;161(Suppl 11):S1-5.
12. Rabe KF, Adachi M, Lai CKW, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004;114:40-7.
13. Fitzgerald JM, Boulet LP, McIvor RA, et al. Asthma control in Canada remains suboptimal: The Reality of Asthma Control (TRAC) study. Can Respir J 2006;13:253-9.
14. Chapman KR. Impact of 'mild' asthma on health outcomes: findings of a systematic search of the literature. Respir Med 2005;99:1350-62.
15. Lemiere C, Bai T, Balter M, et al. Adult asthma consensus guidelines update 2003. Can Respir J 2004;11(Suppl A):9A-18A.
16. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2003. Can Respir J 2003;10(Suppl A):11A-65A.
17. Newman KB, Mason UG 3rd, Schmaling KB. Clinical features of vocal cord dysfunction. Am J Respir Crit Care Med 1995;152:1382-6.
18. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005;127:335-71.
19. Rand CS, Wise RA. Measuring adherence to asthma medication regimens. Am J Respir Crit Care Med 1994;149(Suppl):S69-76.
20. Walewski KM, Cicutto L, D'Urzo AD, et al. Evaluation of a questionnaire to assess compliance with anti-asthma medications. J Asthma 2004;41:77-83.
21. Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004;113:245-51.
22. Chapman KR, Walker L, Cluley S, et al. Improving patient compliance with asthma therapy. Respir Med 2000;94:2-9.
23. Blanc PD, Toren K. How much adult asthma can be attributed to occupational factors? Am J Med 1999;107:580-7.
24. Scadding GK. Other anti-inflammatory uses of intranasal corticosteroids in upper respiratory inflammatory diseases. Allergy 2000;55(Suppl 62):19-23.
25. Bousquet J, Van-Cauwenberge P, Khaltaev N; ARIA Workshop Group. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl 5):S147-334.
26. Littner MR, Leung FW, Ballard ED, et al. Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest 2005:128:1128-35.
27. Boulet LP, Des CA. The link between obesity and asthma: a Canadian perspective. Can Respir J 2007;14:217-20.
28. Stoller JK, Snider GL, Brandy ML, et al. Genetic testing for alpha-1 antitrypsin deficiency - ethical, legal, psychologic, social, and economic issues. Am J Respir Crit Care Med 2003;168:874-96.
29. Agarwal R. Allergic bronchopulmonary aspergillosis. Chest 2009;135:805-26.
30. Grau RG. Churg-Strauss syndrome: 2005-2008 update. Curr Rheumatol Rep 2008;10:453-8.
31. Harrold LR, Andrade SE, Go AS, et al. Incidence of Churg-Strauss syndrome in asthma drug users: a population-based perspective. J Rheumatol 2005:32:1076-80.
32. Nimmagadda SR, Spahn JD, Leung DYM, et al. Steroid-resistant asthma: evaluation and management. Ann Allergy Asthma Immunol 1996;77:345-55.
33. Peake MD, Cayton RM, Howard P. Triamcinolone in corticosteroid-resistant asthma. Br J Dis Chest 1979;73:39-44.
34. Corrigan CJ, Brown PH, Barnes NC, et al. Glucocorticoid resistance in chronic asthma: glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis 1991;144:1016-25.
35. Loftus BG, Price JF, Lobo-Yeo A, Vergani D. IgG subclass deficiency in asthma. Arch Dis Child 1988;63:1434-7.
36. Chapman KR, Cartier A, Hebert J, et al. The role of omalizumab in the treatment of severe allergic asthma. Can Respir J 2006;13(Suppl B):1B-9B.
37. Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy 2009;39:788-97.
38. Cox L, Platts-Mills TA, Finegold I, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007;120:1373-7.
39. Barry PJ, O'Mahony A, Finnegan C, et al. Delayed allergic reactions to omalizumab: Are patients reporting all cases? J Allergy Clin Immunol 2008;121:785-6.
40. Limb SL, Starke PR, Lee CE, et al. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007;120:1378-81.
41. CEDAC final recommendation on reconsideration and reasons for recommendation: omalizumab. Ottawa (ON): Canadian Coordinating Office for Technology Assessment; 2006. Available: www.cadth.ca/media/cdr/complete/cdr- complete-Xolair-March7-06.pdf (accessed 2009 Jul. 30).
42. Wu AC, Paltiel AD, Kuntz KM, et al. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 2007;120:1146-52.
43. Omalizumab for severe persistent allergic asthma. London (UK): National Health Service, National Institute for Health and Clinical Excellence; 2007 Available: www.nice.org.uk/nicemedia/pdf/TA133Guidance.pdf (accessed 2009 Jul. 30).
44. Fanta CH. Asthma. N Engl J Med 2009;360:1002-14.
45. Chapman KR, Cartier A, Hébert J, et al. The role of omalizumab in the treatment of severe allergic asthma. Can Respir J 2006;13(Suppl B):1B-9B.
46. Dyer PD, Vaughan TR, Weber RW. Methotrexate in the treatment of steroid-dependent asthma. J Allergy Clin Immunol 1991;88:208-12.
47. Coffey MJ, Sanders G, Eschenbacher WL, et al. The role of methotrexate in the management of steroid-dependent asthma. Chest 1994;105:117-21.
48. Stewart GE 2nd, Diaz JD, Lockey RF, et al. Comparison of oral pulse methotrexate with placebo in the treatment of severe glucocorticosteroid- dependent asthma. J Allergy Clin Immunol 1994;94:482-9.
49. Marin MG. Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: a meta-analysis. Chest 1997;112:29-33.
50. Shulimzon TR, Shiner RJ. A risk-benefit assessment of methotrexate in corticosteroid-dependent asthma. Drug Saf 1996;15:283-90.
51. Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 1992;339:324-8.
52. Lock SH, Kay AB, Barnes NC. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med 1996;153:509-14.
53. Bernstein IL, Bernstein DI, Dubb JW, et al. A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. J Allergy Clin Immunol 1996;98:317-24.
54. Nierop G, Gijzel WP, Bel EH, et al. Auranofin in the treatment of steroid-dependent asthma: a double-blind study. Thorax 1992;47:349-54.
55. Mazer BD, Gelfand EW. An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma. J Allergy Clin Immunol 1991:87:976-83.
56. Jakobsson T, Croner S, Kjellman NI, et al. Slight steroid-sparing effect of intravenous immunoglobulin in children and adolescents with moderately severe bronchial asthma. Allergy 1994;49:413-20.
57. Niggemann B, Leupold W, Schuster A, et al. Prospective, double-blind, placebo-controlled, multicentre study on the effect of high-dose, intravenous immunoglobulin in children and adolescents with severe bronchial asthma. Clin Exp Allergy 1998;28:205-10.
58. Landwehr LP, Jeppson JD, Katlan MG, et al. Benefits of high-dose i.v. immunoglobulin in patients with severe steroid-dependent asthma. Chest 1998;114:1349-56.
59. Vrugt B, Wilson S, van Velzen E, et al. Effects of high-dose intravenous immunoglobulin in two severe corticosteroid insensitive asthmatic patients. Thorax 1997;52:662-4.
60. Berlow BA, Liebhaber M, Dyer Z, et al. The effect of dapsone in steroid-dependent asthma. J Allergy Clin Immunol 1991;87:710-5.
61. Charous BL. Open study of hydroxychloroquine in the treatment of severe symptomatic or corticosteroid-dependent asthma. Ann Allergy 1990;65:53-8.
62. Leckte MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2144-8.
63. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-93.
64. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84.
65. Flood-Page P, Swenson C, Faiferman I, et al.; International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007:176:1062-71.
66. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563. Drugs R D 2008;9:125-30.
67. Bryan SA, O'Connor BJ, Matti S, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2149-53.
68. Cox G, Miller J, Mitzner W, et al. Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: rationale and preliminary investigations. Eur Respir J 2004;24:659-63.
69. Cox PG, Miller JD, McWilliams A, et al. Bronchial thermoplasty for asthma. Am J Respir Crit Care Med 2006;173:965-9.
70. Pavord ID, Cox G, Thomson NC, et al. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med 2007;176:1185-91.
71. Cox G, Thomson NC, Rubin AS, et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007;356:1327-37.
72. McCamey RW, Linde K, Lasserson TJ. Homeopathy for chronic asthma [review]. Cochrane Database Syst Rev 2004;(1):CD000353.
73. White A, Slade P, Hunt C, et al. Individualised homeopathy as an adjunct in the treatment of childhood asthma: a randomised placebo controlled trial. Thorax 2003,58:317-21.
74. Lewith GT, Watkins AD, Hyland ME, et al. Use of ultramolecular potencies of allergen to treat asthmatic people allergic to house dust mite: double blind randomised controlled clinical trial. BMJ 2002:324:520.
75. McCarney RW, Lasserson TJ, Linde K, et al. An overview of two Cochrane systematic reviews of complementary treatments for chronic asthma: acupuncture and homeopathy. Respir Med 2004;98:687-96.
76. Hondras MA, Linde K, Jones AP. Manual therapy for asthma [review]. Cochrane Database Syst Rev 2005;(2):CD001002.
77. Martin J, Donaldson AN, Villarroel R, et al. Efficacy of acupuncture in asthma: systematic review and meta-analysis of published data from 11 randomised controlled trials. Eur Respir J 2002;20:846-52.
78. Brown D. Evidence-based hypnotherapy for asthma: a critical review. Int J Clin Exp Hypn 2007;55:220-49.
79. Huntley A, White AR, Ernst E. Relaxation therapies for asthma: a systematic review. Thorax 2002;57:127-31.
80. Arnold E, Clark CE, Lasserson TJ, et al. Herbal interventions for chronic asthma in adults and children [review]. Cochrane Database Syst Rev 2008;(1):CD005989.
81. Singh BB, Khorsan R, Vinjamury SP, et al. Herbal treatments of asthma: a systematic review. J Asthma 2007;44:685-98.
82. Li XM, Brown L. Efficacy and mechanisms of action of traditional Chinese medicines for treating asthma and allergy. J Allergy Clin Immunol 2009;123:297-306.
83. Price D, Pavord I. Breathing exercises for asthma: a randomised controlled trial. Thorax 2009;64:55-61.
84. Cowie RL, Conley DP, Underwood MF, et al. A randomised controlled trial of the Buteyko technique as an adjunct to conventional management of asthma. Respir Med 2008;102:726-32.
85. Cooper S, Oborne J, Newton S, et al. Effects of two breathing exercises (buteyko and pranayama) in asthma: a randomised controlled trial. Thorax 2003;58:674-9.
86. Holloway E, Ram FS. Breathing exercises for asthma [review]. Cochrane Database Syst Rev 2004;(1):CD001277.
87. Woods RK, Thien FC, Abramson JM. Dietary marine fatty acids (fish oil) for asthma in adults and children [review]. Cochrane Database Syst Rev 2002;(3):CD001283.
88. Kaur B, Rowe BH, Arnold E. Vitamin C supplementation for asthma [review]. Cochrane Database Syst Rev 2009;(1):CD000993.
89. Fogarty A, Lewis SA, Scrivener SL, et al. Oral magnesium and vitamin C supplements in asthma: a parallel group randomized placebo-controlled trial. Clin Exp Allergy 2003;33:1355-9.
90. Nelson HS, Hamilos DL, Corsello PR, et al. A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. Am Rev Respir Dis 1993;147:398-404.
91. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005;60:1012-8.
92. Puxeddu I, Pang YY, Harvey A, et al. The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. J Allergy Clin Immunol 2008;121:1400-6.et